Drug intelligence / Profile preview

CAPCS cooling gel

Development stage: Unknown
Lead developer: CAPCS
Modality: Small Molecules
Administration: Topical

Overview

CAPCS cooling gel is a topical therapeutic product developed by the South Korean company CAPCS Co., Ltd. for the management of atopic dermatitis. The gel functions primarily through a physical cooling mechanism that helps to reduce skin temperature, thereby alleviating pruritus (itching) and the associated inflammatory response. Beyond its cooling properties, the gel acts as a skin barrier protectant, helping to restore the integrity of the epidermal barrier and reduce transepidermal water loss (TEWL), which are key pathological features of atopic dermatitis. It has been investigated in clinical trials in South Korea as a non-steroidal, device-based topical therapy to manage the symptoms of mild to moderate atopic dermatitis.

Brand names: CAPCS cooling gel
Other names: CAPCS gel

Beyond the preview

Go deeper on CAPCS cooling gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAPCS cooling gel.

Explore the full profile